Results 1 to 10 of about 70,715 (255)

JAK2 (janus kinase 2) [PDF]

open access: yesAtlas of Genetics and Cytogenetics in Oncology and Haematology, 2010
Review on JAK2 (janus kinase 2), with data on DNA, on the protein encoded, and where the gene is implicated.
openaire   +2 more sources

Polisitemia vera; aspek klinis dan tatalaksana terbaru

open access: yesJKS (Jurnal Kedokteran Syiah Kuala), 2020
Abstrak. Polisitemia Vera (PV) adalah gangguan kronis klonal mieloproliperatif yang ditandai dengan peningkatan hebat dalam jumlah sel darah merah dan volume darah total, dan biasanya disertai dengan leukositosis, trombositosis dan splenomegali.
Muhammad Riswan   +2 more
doaj   +1 more source

JAK2 (janus kinase 2) [PDF]

open access: yesAtlas of Genetics and Cytogenetics in Oncology and Haematology, 2011
Review on JAK2 (janus kinase 2), with data on DNA, on the protein encoded, and where the gene is implicated.
openaire   +1 more source

JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis

open access: yesBMC Infectious Diseases, 2021
Background The spread of a highly pathogenic, novel coronavirus (SARS-CoV-2) has emerged as a once-in-a-century pandemic, having already infected over 63 million people worldwide. Novel therapies are urgently needed.
Lucas Walz   +6 more
doaj   +1 more source

Development of an enzyme-coupled activity assay for Janus kinase 2 inhibitor screening

open access: yesSLAS Discovery, 2023
JAK2 transmits signals of several important cytokines, such as growth hormone and erythropoietin. The interest toward the therapeutic targeting of JAK2 was boosted in 2005, when the somatic JAK2 V617F mutation, responsible for the majority of ...
Angelika Pölläniemi   +3 more
doaj   +1 more source

Janus kinase 2 negative polycythemia vera [PDF]

open access: yesAsian Biomedicine, 2015
Abstract Background A Janus kinase 2 (JAK2) mutation polycythemia vera (PV) is a common manifestation of stem cell disorder. However, available data on the clinical and treatment response of JAK2-negative PV patients are limited ...
Pravinwan Thungthong   +4 more
openaire   +1 more source

Suggested modification of Janus associated kinase 2-tree algorithm for the detection of Janus associated kinase 2 V617F-positive polycythemia rubra vera patients in Pakistani population

open access: yesJournal of Applied Hematology, 2020
OBJECTIVE: The Janus associated kinase-2 (JAK2 mutation V617F and exon 12) is detected in most polycythemia vera (PV) patients. It can easily be picked up by real-time polymerase chain reaction (PCR).
Mohammad Abdul Naeem, Mohammad Iqbal
doaj   +1 more source

ORF3a Protein of Severe Acute Respiratory Syndrome Coronavirus 2 Inhibits Interferon-Activated Janus Kinase/Signal Transducer and Activator of Transcription Signaling via Elevating Suppressor of Cytokine Signaling 1

open access: yesFrontiers in Microbiology, 2021
Coronavirus disease 2019 (COVID-19) has caused a crisis to global public health since its outbreak at the end of 2019. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen of COVID-19, appears to efficiently evade the host immune ...
Rong Wang   +7 more
doaj   +1 more source

Knockdown of long non-coding RNA HOXD-AS1 inhibits gastric cancer cell growth via inactivating the JAK2/STAT3 pathway

open access: yesTumor Biology, 2017
Long non-coding RNA HOXD-AS1 (HOXD cluster antisense RNA 1) has been demonstrated to be closely associated with the progression of several tumors. However, the biological function of HOXD-AS1 and the underlying molecular mechanism in gastric cancer are ...
Li Zheng   +3 more
doaj   +1 more source

Cholesterol efflux to apoA-I in ABCA1-expressing cells is regulated by Ca2+-dependent calcineurin signaling

open access: yesJournal of Lipid Research, 2010
ATP-binding cassette transporter A1 (ABCA1) is required for the lipidation of apolipoprotein A-I (apoA-I), although molecular mechanisms supporting this process remain poorly defined.
Joel Karwatsky   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy